{"entity":{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","aka":[],"tldr":"Leads kidney cancer research worldwide, including the adjuvant pembrolizumab and belzutifan trials.","summary":"Toni K. Choueiri is Director of the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center. He leads kidney cancer research worldwide, serving as principal investigator on CheckMate 9ER, the KEYNOTE-564 trial of adjuvant pembrolizumab and the LITESPARK studies of the HIF-2 alpha inhibitor belzutifan. His selected papers report adjuvant pembrolizumab after nephrectomy in renal cell carcinoma and belzutifan versus everolimus for advanced renal cell carcinoma. He continues to work on immunotherapy combinations, cabozantinib and HIF-2 alpha inhibition in kidney cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Toni_Choueiri","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":["hif2a","pd1"],"drugs":["pembrolizumab","belzutifan","cabozantinib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["keynote-564","litespark-005","checkmate-9er"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Lank Center for Genitourinary Oncology","institutionId":"dana-farber","specialisms":["Kidney cancer","Immunotherapy combinations","HIF-2α"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D"}],"papers":[{"title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2106391","doi":"10.1056/NEJMoa2106391"},{"title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2313906","doi":"10.1056/NEJMoa2313906"},{"title":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2035716","doi":"10.1056/NEJMoa2035716"}],"orcid":"0000-0002-9201-3217"},"route":"/people/toni-choueiri/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/"},{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/"},{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/"}],"paper":[{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/"},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/"}]}}